GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » ROE %

Lucid Diagnostics (Lucid Diagnostics) ROE % : -35,363.27% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lucid Diagnostics's annualized net income for the quarter that ended in Dec. 2023 was $-43.32 Mil. Lucid Diagnostics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $0.12 Mil. Therefore, Lucid Diagnostics's annualized ROE % for the quarter that ended in Dec. 2023 was -35,363.27%.

The historical rank and industry rank for Lucid Diagnostics's ROE % or its related term are showing as below:

LUCD' s ROE % Range Over the Past 10 Years
Min: -507.97   Med: -144.42   Max: -136.23
Current: -416.21

During the past 5 years, Lucid Diagnostics's highest ROE % was -136.23%. The lowest was -507.97%. And the median was -144.42%.

LUCD's ROE % is ranked worse than
97.77% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 0.125 vs LUCD: -416.21

Lucid Diagnostics ROE % Historical Data

The historical data trend for Lucid Diagnostics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics ROE % Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -136.23 -144.42 -507.97

Lucid Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -236.11 -271.05 -227.75 -644.83 -35,363.27

Competitive Comparison of Lucid Diagnostics's ROE %

For the Medical Devices subindustry, Lucid Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's ROE % distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's ROE % falls into.



Lucid Diagnostics ROE % Calculation

Lucid Diagnostics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-52.666/( (23.047+-2.311)/ 2 )
=-52.666/10.368
=-507.97 %

Lucid Diagnostics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-43.32/( (2.556+-2.311)/ 2 )
=-43.32/0.1225
=-35,363.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Lucid Diagnostics  (NAS:LUCD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-43.32/0.1225
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-43.32 / 4.16)*(4.16 / 30.257)*(30.257 / 0.1225)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1041.35 %*0.1375*246.9959
=ROA %*Equity Multiplier
=-143.19 %*246.9959
=-35,363.27 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-43.32/0.1225
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-43.32 / -43.32) * (-43.32 / -45.812) * (-45.812 / 4.16) * (4.16 / 30.257) * (30.257 / 0.1225)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9456 * -1101.25 % * 0.1375 * 246.9959
=-35,363.27 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Lucid Diagnostics ROE % Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics (Lucid Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165